期刊
NATURE BIOTECHNOLOGY
卷 39, 期 8, 页码 928-+出版社
NATURE PORTFOLIO
DOI: 10.1038/s41587-021-00878-8
关键词
-
资金
- Harry and Dianna Hind Endowed Professorship in Pharmaceutical Sciences
- Chan Zuckerberg Biohub
- National Science Foundation [1650113]
- Merck Fellowship of the Damon Runyon Cancer Research Foundation [DRG-2297-17]
- National Institutes of Health K99/R00 award [1K99EB030587-01]
- National Institutes of Health National Cancer Institute F32 [5F32CA239417]
- Merck Postdoctoral Research Fellowship from the Helen Hay Whitney Foundation
- National Institutes of Health K99/R00 [1K99GM135529]
- NIH/NIAID [3R01AI141003-03S1, U19AI111825, R01AI139119]
- Fast Grants
- CEND COVID Catalyst Fund
- Rockefeller University Center for Clinical and Translational Science Grant [UL1 TR001866]
- Chan Zuckerberg Biohub, Rapid Response
A rapid and low-cost solution-based assay has been developed to detect SARS-CoV-2 antibodies in serum, plasma, whole blood, and to some extent saliva, using split luciferase antibody biosensors. This new method generates quantitative results in 30 minutes, simplifying the complexity and improving the scalability of COVID-19 antibody tests. It is suitable for point-of-care testing, population screening, and use in low-resource settings for monitoring host humoral responses to vaccination or viral infection.
Current serology tests for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) antibodies mainly take the form of enzyme-linked immunosorbent assays, chemiluminescent microparticle immunoassays or lateral flow assays, which are either laborious, expensive or lacking sufficient sensitivity and scalability. Here we present the development and validation of a rapid, low-cost, solution-based assay to detect antibodies in serum, plasma, whole blood and to a lesser extent saliva, using rationally designed split luciferase antibody biosensors. This new assay, which generates quantitative results in 30 min, substantially reduces the complexity and improves the scalability of coronavirus disease 2019 (COVID-19) antibody tests. This assay is well-suited for point-of-care, broad population testing, and applications in low-resource settings, for monitoring host humoral responses to vaccination or viral infection. A rapid, split luciferase test for SARS-CoV-2 antibodies in blood and saliva compatible with lyophilization and use in low-resource settings.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据